Stonepine Capital Management LLC Buys New Shares in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX)

Stonepine Capital Management LLC purchased a new position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals accounts for 0.8% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 16th biggest position. Stonepine Capital Management LLC owned approximately 6.86% of Kiora Pharmaceuticals as of its most recent SEC filing.

Kiora Pharmaceuticals Price Performance

Shares of KPRX opened at $3.66 on Tuesday. The firm has a fifty day moving average price of $3.76 and a 200 day moving average price of $4.65. Kiora Pharmaceuticals, Inc. has a 1-year low of $3.00 and a 1-year high of $8.98.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its quarterly earnings results on Friday, August 9th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.42. The firm had revenue of $0.02 million for the quarter. As a group, equities analysts expect that Kiora Pharmaceuticals, Inc. will post 1.17 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Kiora Pharmaceuticals in a research report on Thursday, August 22nd. Maxim Group upgraded Kiora Pharmaceuticals to a “strong-buy” rating in a report on Thursday, June 13th.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.